Journal of Cancer Research and Clinical Oncology

, Volume 139, Issue 2, pp 187–194

Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy

  • Vesna Bišof
  • Antonija Jakovčević
  • Sven Seiwerth
  • Zoran Rakušić
  • Slavko Gašparov
Original Paper

DOI: 10.1007/s00432-012-1318-8

Cite this article as:
Bišof, V., Jakovčević, A., Seiwerth, S. et al. J Cancer Res Clin Oncol (2013) 139: 187. doi:10.1007/s00432-012-1318-8

Abstract

Purpose

To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinoma patients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR).

Methods

ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed.

Results

High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21).

Conclusions

ERCC1 expression had no predictive value in head and neck carcinoma patients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.

Keywords

Head and neck carcinoma Radiotherapy Prognostic value ERCC1 

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Vesna Bišof
    • 1
  • Antonija Jakovčević
    • 2
  • Sven Seiwerth
    • 2
  • Zoran Rakušić
    • 1
  • Slavko Gašparov
    • 3
  1. 1.Department of OncologyUniversity Hospital ZagrebZagrebCroatia
  2. 2.Department of Pathology and CytologyUniversity Hospital ZagrebZagrebCroatia
  3. 3.Department of Pathology and CytologyUniversity Hospital MerkurZagrebCroatia

Personalised recommendations